Calithera Biosciences (NASDAQ:CALA) Now Covered by StockNews.com
Calithera Biosciences (NASDAQ:CALA) Now Covered by StockNews.com
Stock analysts at StockNews.com began coverage on shares of Calithera Biosciences (NASDAQ:CALA – Get Rating) in a research note issued on Monday. The brokerage set a "hold" rating on the biotechnology company's stock.
股票分析師在股票新聞網開始覆蓋的股票 卡利瑟拉生物科學 (納斯達克:卡拉 — 獲得評級) 在星期一發布的研究報告中。經紀公司對生物技術公司的股票設定了「持有」評級。
A number of other research analysts have also weighed in on the stock. LADENBURG THALM/SH SH lowered shares of Calithera Biosciences from a "buy" rating to a "neutral" rating in a report on Tuesday, November 15th. SVB Leerink lowered shares of Calithera Biosciences from an "outperform" rating to a "market perform" rating in a report on Tuesday, November 15th.
一些其他研究分析師也對股票進行了權衡。拉登堡 THALM/SH SH 在 11 月 15 日（星期二）的一份報告中，將卡利瑟拉生物科學的股票從「買入」評級降至「中性」評級。在 11 月 15 日（星期二）的報告中，SVB Leerink 將卡利瑟拉生物科學的股票從「跑贏大市」評級降至「市場表現」評級。
Calithera Biosciences Stock Performance
卡利瑟拉生物科學股票表現
CALA stock opened at $0.38 on Monday. The firm has a fifty day moving average price of $1.75 and a 200 day moving average price of $2.67. Calithera Biosciences has a fifty-two week low of $0.36 and a fifty-two week high of $14.87. The firm has a market cap of $1.85 million, a PE ratio of -0.01 and a beta of 1.31.
卡拉股票週一以 0.38 美元開盤。該公司的五十天移動平均價格為 1.75 美元，200 日移動平均價格為 2.67 美元。卡利瑟拉生物科學有五十兩周低點 $0.36 和五十二周高點 14.87 美元。該公司的市值為 85 萬美元，私募股權比率為 -0.01，測試值為 1.31。
Institutional Inflows and Outflows
機構流入和流出
Institutional investors and hedge funds have recently bought and sold shares of the company. Alyeska Investment Group L.P. bought a new stake in shares of Calithera Biosciences during the first quarter worth $404,000. Affinity Asset Advisors LLC bought a new stake in shares of Calithera Biosciences during the first quarter worth $404,000. Renaissance Technologies LLC lifted its position in shares of Calithera Biosciences by 36.5% during the first quarter. Renaissance Technologies LLC now owns 1,853,500 shares of the biotechnology company's stock worth $749,000 after purchasing an additional 496,100 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Calithera Biosciences by 143.2% during the first quarter. Goldman Sachs Group Inc. now owns 123,739 shares of the biotechnology company's stock worth $50,000 after purchasing an additional 72,865 shares during the last quarter. Finally, Vanguard Group Inc. lifted its position in shares of Calithera Biosciences by 23.4% during the third quarter. Vanguard Group Inc. now owns 141,217 shares of the biotechnology company's stock worth $415,000 after purchasing an additional 26,800 shares during the last quarter. 33.73% of the stock is owned by hedge funds and other institutional investors.
機構投資者和對沖基金最近買賣了該公司的股票。阿麗斯卡投資集團有限責任公司在第一季度收購了卡利瑟拉生物科學股份的新股份 404,000 美元。親和資產顧問有限責任公司在第一季度購買了卡利瑟拉生物科學股份的新股份 404,000 美元。文藝復興技術有限責任公司在第一季度提升了其在卡利塞拉生物科學股份的地位 36.5%.文藝復興技術有限責任公司現在擁有 1,853,500 股生物技術公司的股票價值 $749,000 在上一個季度購買了另外 496,100 股之後。高盛集團公司在第一季度提升了其在卡利塞拉生物科學股份的地位 143.2％。高盛集團在上一季度額外購買 72,865 股股票後，現在擁有該生物技術公司股票的 123,739 股價值 50,000 美元。最後，先鋒集團公司在第三季度上升了 23.4％ 在卡利瑟拉生物科學的股份地位。領航集團股份有限公司在上一季度額外購買 26,800 股股份後，擁有該生物科技公司股票的 141,217 股價值 415,000 元。33.73％ 的股票由對沖基金和其他機構投資者擁有。
Calithera Biosciences Company Profile
卡利瑟拉生物科學公司簡介
(Get Rating)
(取得評分)
Calithera Biosciences, Inc is a clinical-stage biopharmaceutical company, which focuses on discovering and developing small molecule drugs that target novel and critical metabolic pathways in tumor and cancer-fighting immune cells. It offers programs such as Pipeline, Glutaminase Inhibitor, and Arginase Inhibitor.
Calithera Biosciences, Inc 是一家臨床階段生物製藥公司，致力於發現和開發針對腫瘤和抗癌免疫細胞中新穎和關鍵代謝途徑的小分子藥物。它提供了程序，如管道, 谷氨酰胺酶抑制劑, 和精氨酸酶抑制劑.
Featured Stories
特色故事
- Get a free copy of the StockNews.com research report on Calithera Biosciences (CALA)
- eHealth Stock Rises from the Ashes. Time to Get In?
- Can Yext A.I. Search Platform Drive Growth in 2023?
- Cassava Sciences Stock Undervalued with Its $124 Price Target?
- Constellation Brands: Are Consumers Trading Down for Rail Drinks?
- Capital One Stock: Will Subprime Borrowers Spoil the Rally?
- 獲取有關卡利瑟拉生物科學研究報告的免費副本
- 醫健通股票從灰燼中升起。是時候進去了嗎？
- Yext 人工智能搜尋平台能在 2023 年推動增長嗎？
- 木薯科學股票被低估，其 124 美元的目標價格？
- 星座品牌：消費者是否會因鐵路飲料而下跌？
- 資本一股：次級借款人會破壞集會嗎？
Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接收卡利塞拉生物科學日報的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件時事通訊接收有關 Calithera 生物科學及相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。